Details of the Drug Reposition

General Information of This Drug (ID: DMIZ6W2)

Drug Name
Norfloxacin   DMIZ6W2
Synonyms
Baccidal; Barazan; Chibroxin; Fulgram; Lexinor; NFLX; Norflo; Norfloxacine; Norfloxacino; Norfloxacinum; Noroxin; Sebercim; Merck Brand of Norfloxacin; Norfloxacin Merck Brand; AM 0715; AM 715; AM0715; MK 0366; MK 366; MK0366; MK366; AM-0715; AM-715; Chibroxin (TN); Insensye (TN); MK-0366; MK-366; Norflohexal (TN); Norfloxacine [INN-French]; Norfloxacino [INN-Spanish]; Norfloxacinum [INN-Latin]; Norfocin (TN); Noroxin (TN); Nufloxib (TN); Roxin (TN); Utin (TN); Utinor (TN); Apo-Norflox (TN); Norfloxacin (JP15/USP/INN); Norfloxacin [USAN:BAN:INN:JAN]; Chibroxin, MK-366, Baccidal, Sebercim, Zoroxin, Norfloxacin; 1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
Therapeutic Class
Antibiotics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
21 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Streptococcal pneumonia DIS2EKMJ N.A. Approved [1]
Staphylococcus aureus infection DISK6PTH N.A. Approved [1]
Staphylococcal pneumonia DIS28ZSZ N.A. Approved [1]
Pyelonephritis DISAOX93 N.A. Approved [1]
Prostatitis DISL8OGN N.A. Approved [1]
Peritonitis DISMCMLQ N.A. Approved [1]
Mycoplasma pneumoniae pneumonia DIS1AW2Z N.A. Approved [1]
Malignant otitis externa caused by Pseudomonas aeruginosa DIS5C8KP N.A. Approved [1]
Endomyometritis DIS9WIQU N.A. Approved [1]
Chronic tubotympanic suppurative otitis media DIS7R96F N.A. Approved [1]
Chancroid DISMVLOF N.A. Approved [1]
Acute maxillary sinusitis DISEUB5R N.A. Approved [1]
Acute gonococcal cervicitis DIS4LKDT N.A. Approved [1]
Bacterial infection DIS5QJ9S 1A00-1C4Z Approved [2]
Bacillary dysentery DISFZHKN 1A02 Approved [1]
Anthrax DISFPT78 1B97 Approved [1]
Bronchitis DISBM6EQ CA20 Approved [1]
Pneumonia DIS8EF3M CA40 Approved [1]
Cystitis DIS2D4B9 GC00 Approved [1]
Urinary tract infection DISMT6UV GC08 Approved [1]
Traveler's diarrhea DIS4R0UE ME05.1 Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 21 Indications(s)
2 Withdrawn Indication(s)
Indication Name Indication ID ICD-11 Status REF
Peritonsillar abscess DISZZXTZ N.A. Withdrawn [3]
Acute gonococcal endometritis DISZ8BW7 N.A. Withdrawn [4]
------------------------------------------------------------------------------------
1 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Otitis externa DISYCORK AA00-AA13 Discontinued in Phase 3 [5]
------------------------------------------------------------------------------------
4 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Bacterial conjunctivitis DIST79FU N.A. Discontinued in Phase 2 [6]
Rhinoscleroma DISNSWVK N.A. Discontinued in Phase 2 [7]
Bacterial urinary tract infection DISNNJTF N.A. Discontinued in Phase 2 [8]
Typhoid fever DISP3NHR 1A07 Discontinued in Phase 2 [9]
------------------------------------------------------------------------------------
2 Discontinued in Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Escherichia coli infection DISPP65M 1A03 Discontinued in Phase 1 [10]
Gonorrhea DISQ5AO6 1A7Z Discontinued in Phase 1 [11]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Pneumonia caused by chlamydia DISX7CHR N.A. Investigative [1]
------------------------------------------------------------------------------------

References

1 Norfloxacin FDA Label
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074690.
3 Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression
4 The Use of Domperidone for Gastroparesis
5 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
6 VELCADE,Rituximab,Cyclophosphamide and Decadron
7 Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma
8 Modafinil for Methamphetamine Dependence
9 Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
10 ClinicalTrials.gov (NCT00096005) Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
11 Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer